Jan 12, 2026 | Acquisition Cost Index (ACI), Biosimilar, Brand Name Drugs, Drug costs, High-value formulary, MedBen Rx, News, Patient assistance program, Pharmacogenomics, Rx Costs, Rx prices
Pharmaceutical manufacturers are planning to raise list prices on at least 350 brand-name medications in the United States beginning in 2026, up from 250 drugs last year, according to new data from health care research firm 3 Axis Advisors. These increases reflect...
Jul 11, 2025 | Comparative Effectiveness, Cost Savings, Drug costs, Evidence-based research, Formularies, High-value formulary, MedBen Rx, Rx Advertising, Rx Costs, Rx prices, Rx Spending
Pharmaceutical advertising hit a record high in 2024, with the top 10 drugs accounting for $3.3 billion in ad spending – up nearly 20% from the previous year. With more campaigns directly targeting consumers, MedBen Rx’s high-value formulary educates members about...
Aug 7, 2023 | Access solutions, Case Study, Limited Use HRA, MedBen Rx, Patient advocacy program, Prescription drugs, Rx Costs, Rx prices, Rx Spending, Savings, Specialty Drugs
With specialty drugs now making up about half of total drug spending – and poised to go even higher as more new specialty drugs roll out every year – the need for workable access solutions grows. Fortunately, MedBen Rx has them. Our unique approach incorporates a...
Jul 11, 2023 | Brand Name Drugs, Generic Drugs, MedBen Rx, Pharmacies, Pharmacy Benefits Manager (PBM), Prescription drugs, Rx Costs, Rx prices, Rx Spending, Savings, Specialty Drugs, Transparency, Value
A new playbook from the National Alliance of Healthcare Purchaser Coalitions lists the top 10 concerns employer health plans have with pharmacy benefit managers (PBMs): Promoting drugs with higher prices when lower-price options are availableOffering preferred...
May 16, 2023 | Access solutions, Announcements, Client Report, Cost Plus, MedBen, MedBen Rx, Mobile app, Online Services, Prescription drugs, Rx Costs, Rx prices, Rx Spending, Savings, Specialty Drugs
The 2023 MedBen Client Report is now available to download from MedBen.com! In his opening note, MedBen President Kurt Harden states: “This Client Report is designed to demonstrate ways that clients can generate greater value from their health plan....
Mar 21, 2023 | Brand Name Drugs, Diabetes, Generic Drugs, MedBen Rx, MedBen University, Pharmacy Benefits Manager (PBM), Prescription drugs, Rx Costs, Rx prices, Savings
Earlier this month, drug manufacturer Eli Lilly announced that it cutting the cost of two of its prescription brand insulins, Humalog and Humulin, by 70%, and capping out-of-pocket costs for privately insured patients at $35 a month. Competing...
